SEARCH

SEARCH BY CITATION

References

  • 1
    Chapman RW, Arborgh BAM, Rhodes JM, Summerfield JA, Dick R, Scheuer PJ. Primary sclerosing cholangitis: A review of clinical features, cholangiography and hepatic histology. Gut 1980; 21: 870877.
  • 2
    Wiesner RH, Grambsch PM, Dickson ER, Ludwig J, MacCarty RL, Hunter EB, et al. Primary sclerosing cholangitis: Natural history, prognostic factors and survival analysis. HEPATOLOGY 1989; 10: 430436.
  • 3
    Angulo P, Lindor, KD. Primary sclerosing cholangitis. HEPATOLOGY 1999; 30: 325332.
  • 4
    MacFaul GR, Chapman RW. Sclerosing cholangitis. Curr Opin Gastroenterol 2005; 21: 348353.
  • 5
    Talwalkar JA, Lindor KD. Primary sclerosing cholangitis. Inflamm Bowel Dis 2005; 11: 6272.
  • 6
    Bambha K, Kim WR, Talwalker J, Torgerson H, Benson JT, Therneau TM, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003; 125: 13641369.
  • 7
    Ludwig J. Small-duct primary sclerosing cholangitis. Semin Liver Dis 1991; 11: 1117.
  • 8
    Angulo P, Maor-Kendler Y, Lindor KD. Small-duct primary sclerosing cholangitis: A long-term follow-up study. HEPATOLOGY 2002; 35: 14941500.
  • 9
    Bjornsson E, Boberg KM, Cullen S, Fleming K, Clausen OP, Fausa O, et al. Patients with small duct primary sclerosing cholangitis have a favourable long-term prognosis. Gut 2002; 51: 731735.
  • 10
    Schrumpf E, Boberg KM. Epidemiology of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2001; 15: 553562.
  • 11
    Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: A 16 year prospective study. HEPATOLOGY 2001; 33: 544553.
  • 12
    Abdo AA, Bain VG, Kichian K, Lee SS. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: sequential syndrome. HEPATOLOGY 2002; 36: 13931399.
  • 13
    Roberts EA. Primary sclerosing cholangitis in children. J Gastroenterol Hepatol 1999; 14: 588593.
  • 14
    Jaffe R. Liver involvement in the histiocytic disorders of childhood. Pediatr Dev Pathol 2004; 7: 214225.
  • 15
    Rodrigues F, Davies EG, Harrison P, McLauchlin J, Karani J, Portmann B, et al. Liver disease in children with primary immunodeficiencies. J Pediatr 2004; 145: 333339.
  • 16
    Durieu I, Pellet O, Simonot L, Durupt S, Bellon G, Durand DV, et al. Sclerosing cholangitis in adults with cystic fibrosis: A magnetic resonance cholangiographic prospective study. J Hepatol 1999; 30: 10521056.
  • 17
    Baker AJ, Portmann B, Westaby D, Wilkinson M, Karani J, Mowat AP. Neonatal sclerosing cholangitis in two siblings: A category of progressive intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 1993; 17: 317323.
  • 18
    Debray D, Pariente D, Urvoas E, Hadchouel M, Bernard O. Sclerosing cholangitis in children. J Pediatr 1994; 124: 4956.
  • 19
    Wilschanski M, Chait P, Wade JA, Davis L, Corey M, St. Louis P, et al. Primary sclerosing cholangitis in 32 children: Clinical, laboratory, and radiographic features with survival analysis. HEPATOLOGY 1995; 22: 14151422.
  • 20
    Feldstein AE, Perrault J, El-Youssif M, Lindor KD, Freese DK, Angulo P. Primary sclerosing cholangitis in children: A long-term follow-up study. HEPATOLOGY 2003; 38: 210217.
  • 21
    Floreani A, Rozzotto ER, Ferrara F, Carderi I, Caroli D, Blasone L, et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005; 100: 15161522.
    Direct Link:
  • 22
    El-Shabrawi M, Wilkinson ML, Portmann B, Mieli-Vergani G, Chong SKF, Williams R, et al. Primary sclerosing cholangitis in childhood. Gastroenterology 1987; 92: 12261235.
  • 23
    Ferrara C, Valeri G, Salvolini L, Giovagnoni A. Magnetic resonance cholangiopancreatography in primary sclerosing cholangitis in children. Pediatr Radiol 2000; 32: 413417.
  • 24
    Broome U, Glaumann H, Lindstom E, Loof L, Almer S, Prytz H, et al. Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC). J Hepatol 2002; 36: 586589.
  • 25
    Farrant JM, Hayllar KM, Wilkinson ML, Karani J, Portmann BC, Westaby D, et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991; 100: 17101717.
  • 26
    Dickson ER, Murtaugh PA, Wiesner RH, Grambsch PM, Fleming TR, Ludwig J, et al. Primary sclerosing cholangitis: Refinement and validation of survival models. Gastroenterology 1992; 103: 18931901.
  • 27
    Broome U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielsson A, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38: 610615.
  • 28
    Okolicsanyi L, Fabris L, Viaggi S, Carulli N, Podda M, Ricci G. Primary sclerosing cholangitis: an Italian multicentre study. The Italian PSC Study Group. Eur J Gastroenterol Hepatol 1996; 8: 685691.
  • 29
    Kim WR, Therneau TM, Wiesner RH, Poterucha JJ, Benson JT, Malinchoc M, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000; 75: 688694.
  • 30
    Shetty K, Rybicki L, Carey WD. The Child-Pugh classification as a prognostic indicator for survival in primary sclerosing cholangitis. HEPATOLOGY 1997; 25: 10491053.
  • 31
    Kim WR, Poteruch JJ, Wiesner RH, LaRusso NF, Lindor KD, Petz J, et al. The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. HEPATOLOGY 1999; 29: 164168.
  • 32
    Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998; 33: 99103.
  • 33
    Kingham JGC, Kochar N, Gravenor MB. Incidence, clinical pattern, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology 2004; 126: 19291930.
  • 34
    Escorsell A, Parés A, Rodés J, Solis-Herruzo JA, Miras M, Morena de la E. Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver. J Hepatol 1994; 21: 787791.
  • 35
    Ang TL, Fock KM, Ng TM, Teo EK, Chua TS, Tan JY-L. Clinical profile of primary sclerosing cholangitis in Singapore. J Gastroenterol Hepatol 2002; 17: 908913.
  • 36
    Hurlburt KJ, McMahon BJ, Deubner H, Hsu-Trawinski B, Williams JL, Kowdley KV. Prevalence of autoimmune liver disease in Alaska natives. Am J Gastroenterol 2002; 97: 24022407.
    Direct Link:
  • 37
    Kochhar R, Goenka MK, Das K, Nagi B, Bhasin DK, Chawla YK, et al. Primary sclerosing cholangitis: An experience from India. J Gastroenterol Hepatol 1996; 11: 429433.
  • 38
    Takikawa H, Manabe T. Primary sclerosing cholangitis in Japan: Analysis of 192 cases. J Gastroenterol 1997; 32: 134137.
  • 39
    Rasmussen HH, Fallingborg JF, Mortensen PB, Vyberg M, Tage-Jensen U, Rasmussen SN. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn's disease. Scand J Gastroenterol 1997; 32: 604610.
  • 40
    Olsson R, Danielsson A, Järnerot G, Lindström E, Lööf L, Rolny P, et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastoenterology 1991; 100: 13191323.
  • 41
    Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995; 332: 924933.
  • 42
    Cullen SN, Chapman, RW. Current management of primary sclerosing cholangitis. Aliment Pharmacol Ther 2005; 21: 933948.
  • 43
    Angulo P, Pearce DH, Johnson CD, Henry JJ, Petersen BT, LaRusso NF, et al. Magnetic resonance cholangiography in the evaluation of the biliary tree: Its role in patients with primary sclerosing cholangitis. J Hepatol 2000; 33: 520527.
  • 44
    Vitellas KM, Enns RA, Keogan MT, Freed KS, Spritzer E, Baillie J, et al. Comparison of MR cholangio-pancreatographic techniques with contrast-enhanced cholangiography in the evaluation of sclerosing cholangitis. Am J Roentgenol 2002; 178: 327334.
  • 45
    Burak KW, Angulo P, Lindor KD. Is there a role for liver biopsy in primary sclerosing cholangitis? Am J Gastroenterol 2003; 98: 11551158.
    Direct Link:
  • 46
    Mulder AH, Horst G, Haagsma EB, Limburg PC, Kleibeuker JH, Kallenberg CG. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver disease. HEPATOLOGY 1993; 17: 411417.
  • 47
    Mieli-Vergani G, Vergani D. Sclerosing cholangitis in the paediatric patient. Best Pract Res Clin Gastroenterol 2001; 15: 681690.
  • 48
    MacCarty RL, LaRusso NF, Wiesner, RH, Ludwig J. Primary sclerosing cholangitis: Findings on cholangiography and pancreatography. Radiology 1983; 149: 3944.
  • 49
    Fulcher AS, Turner MA, Franklin KJ, Shiffman M, Sterling RK, Luketic VA, et al. Primary sclerosing cholangitis: Evaluation with MR cholangiography—a case control study. Radiology 2000; 215: 7180.
  • 50
    Revelon G, Rashid A, Kawamoto S, Bluemke DA. Primary sclerosing cholangitis: MR imaging findings with pathologic correlation. Am J Roentgenol 1999; 173: 10371042.
  • 51
    Talwalkar JA, Angulo P, Johnson CD, Petersen BT, Lindor KD. Cost-miminization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. HEPATOLOGY 2004; 40: 3945.
  • 52
    Portmann BC, Nakanuma Y. Biliary disorders. In: MacSweenRNM, BurtAD, IshakKG, ScheuerPJ, AnthonyPP, eds. Pathology of the Liver. 4th ed. London, UK: Churchill Livingstone; 2001: 435506.
  • 53
    Ludwig JLN, Wiesner RH. Primary sclerosing cholangitis. In: PetersRL, ed. Contemporary Issues in Surgical Pathology: Liver Pathology. New York, NY: Churchill Livingstone; 1986: 193213.
  • 54
    Thung SN, Gerber, MA. Primary biliary cirrhosis vs. primary sclerosing cholangitis. In: Differential Diagnosis in Pathology: Liver Disorders. New York, NY: Igaku-Shoin; 1995: 5255.
  • 55
    Gossard AA, Angulo P, Lindor KD. Secondary sclerosing cholangitis. A comparison to primary sclerosing cholangitis. Am J Gastroenterol 2005; 100: 13301333.
    Direct Link:
  • 56
    Beuers U, Rust C. Overlap syndromes. Semin Liver Dis 2005; 25: 311320.
  • 57
    Nakanuma Y, Hoso M, Sanzen T, Sasaki M. Microstructure and development of the normal and pathologic biliary tract in humans, including blood supply. Microsc Res Tech 1997; 38: 552570.
  • 58
    Lazaridis KN, Strazzabosco M, LaRusso NF. The cholangiopathies: Disorders of biliary epithelia. Gastroenterology 2004; 127: 15651577.
  • 59
    Tietz PS, LaRusso NF. Cholangiocyte biology. Curr Opin Gastroenterol 2005; 21: 337343.
  • 60
    Donaldson PT. Genetics of liver disease: Immunogenetics and disease pathogenesis. Gut 2004; 53: 599608.
  • 61
    Bergquist A, Lindberg G, Saarinen S, Broome U. Increased prevalence of primary sclerosing cholangitis among first-degree relatives. J Hepatol 2005; 42: 252256.
  • 62
    Donaldson PT, Norris S. Evaluation of the role of MHC class II alleles, haplotypes and selected amino acid sequences in primary sclerosing cholangitis. Autoimmunity 2002; 35: 555564.
  • 63
    Norris S, Kondeatis E, Collins R, Satsangi J, Clare M, Chapman R, et al. Mapping MHC-encoded susceptibility and resistance in primary sclerosing cholangitis: The role of MICA polymorphism. Gastroenterology 2001; 120: 14751482.
  • 64
    Pauli-Magnus C, Kerb R, Fattinger K, Lang T, Anwald B, Kullah-Ublick GA, et al. BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis. HEPATOLOGY 2004; 39: 779791.
  • 65
    McGovern DPB, Hysi P, Ahmad T, van Heel DA, Moffatt MF, Carey A, et al. Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. Hum Mol Genet 2005; 14: 12451250.
  • 66
    Sheth S, Shea JC, Bishop MD, Chopra S, Regan MM, Malmberg E, et al. Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis. Hum Genet 2003; 113: 286292.
  • 67
    Vierling JM. Animal models for primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2001; 15: 591610.
  • 68
    Vierling JM. Animal models of autoimmune diseases of the liver. In: GershwinME, VierlingJM, MannsMP, eds. Liver Immunology. Philadelphia, PA: Hanley & Belfus, Inc.; 2003: 263290.
  • 69
    Vierling, JM, Braun M, Wang H. Immunopathogenesis of vanishing bile duct syndromes. In: AlpiniG, AlvaroD, LeSageG, LaRussoN, eds. Pathophysiology of the Biliary Epithelia. Georgetown, TX: Landes Bioscience and Eurekah.com; 2003: 349375.
  • 70
    Lichtman SN, Okoruwa EE, Keku J, Schwab JH, Sartor RB. Degradation of endogenous bacterial cell wall polymers by the muralytic enzyme mutanolysin prevents hepatobiliary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth. Clin Invest 1992; 90: 13131322.
  • 71
    Koga H, Sakisaka S, Yoshitake M, Harada M, Kumemura H, Hanada S, et al. Abnormal accumulation of lipopolysaccharide in biliary epithelial cells of rats with self-filling blind loops. Int J Mol Med 2002; 9: 621626.
  • 72
    Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med 1998; 339: 12171227.
  • 73
    Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Weiglein AH, Lammert F, et al. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002; 123: 12381251.
  • 74
    Fickert P, Fuchsbichler A, Wagner M, Zollner G, Kaser A, Tilg H, et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knock-out mice. Gastroenterology 2004; 127: 261274.
  • 75
    Pauli-Magnus C, Kerb R, Fattinger K, Lang T, Anwald B, Kullah-Ublick GA, et al. BSEP and MDR3 haplotype structure in healthy Caucasian, primary biliary cirrhosis and primary sclerosing cholangitis. HEPATOLOGY 2004; 39: 779791.
  • 76
    Rosmorduc O, Hermelin B, Boelle PY, Poupon RE, Poupon R, Chazoilleres O. ABCB4 gene mutations and primary sclerosing cholangitis. Gastroenterology 2004; 126: 12201222.
  • 77
    Sheth S, Shea JC, Bishop MD, Chopra S, Regan MM, Malmberg E, et al. Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis. Hum Genet 2003; 113: 286292.
  • 78
    Gallegos-Orozco JF, Eyurk C, Wang N, Rakela J, Charlton MR, Cutting GR, Balan V. Lack of association of common cystic fibrosis transmembrane conductance regulator gene mutations with primary sclerosing cholangitis. Am J Gastroenterol 2005; 100: 874878.
    Direct Link:
  • 79
    Giordon E, Sternber D, Chazouilleres O, Cazeneuve C, Huot D, Calmus Y, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene defects in patients with primary sclerosing cholangitis. J Hepatol 2002; 37: 192197.
  • 80
    Trauner M, Wagner M, Fickert P, Zollner G. Molecular regulation of hepatobiliary transport systems: Clinical implications for understanding and treating cholestasis. J Clin Gastroenterol 2005; 39: 111124.
  • 81
    Spirli C, Nathanson MH, Fiorotto R, Duner E, Denson LA, Sanz JM, et al. Proinflammatory cytokines inhibit secretion in rat bile duct epithelium. Gastroenterology 2001; 121: 156169.
  • 82
    Spirli C, Fabris L, Duner E, Fiorotto R, Ballardini G, Roskams T, et al. Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangocytees. Gastroenterology 2003; 124: 737753.
  • 83
    Geuken E, Visser D, Kuipers F, Blokzijl H, Leuvenink HG, deJong PK, et al. Rapid increase of bile salt secretion is associated with bile duct injury after human liver transplantation. J Hepatol 2004; 41: 10171025.
  • 84
    Zollner G, Gickert P, Silbert D, Fuchsbichler A, Marschall HU, Zatloukal K, et al. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol 2003; 3: 717727.
  • 85
    Medina JF, Martínez-Ansó E, Vázquez JJ, Prieto J. Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. HEPATOLOGY 1997; 25: 1217.
  • 86
    Oswald M, Kullak-Ublick GA, Paumgartner G, Beuers U. Expression of hepatic transporters OATP-C and MRP in primary sclerosing cholangitis. Liver 2001; 21: 247253.
  • 87
    Fickert P, Wagner M, Marshall H-U, Fuchsbichler A, Zollner G, Tsybrovskyy O, et al. 24-norursodeoxycholic acid is superior to ursodeoxycholic acid in the treatement of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006; 130: 465481.
  • 88
    Vierling JM. Is primary sclerosing cholangitis an autoimmune disease? In: LeuschnerU, BrooméU, StiehlA, eds. Cholestatic Liver Diseases: Therapeutic Options & Perspectives. Kluwer Academic Publishers, Dordrecht, Netherlands; 2004; 24: 243246.
  • 89
    Cullen SN, Chapman RW. Primary sclerosing cholangitis. Autoimmun Rev 2003; 2: 305312.
  • 90
    Bansi D, Fleming KA, Chapman R. Importance of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and ulcerative colitis: Prevalence, titre, and IgG subclass. Gut 1996; 38: 384389.
  • 91
    Terjung B, Muennich M, Gottwein J, Soehne J, Worman HJ, Sauerbruch T, et al. Identification of myeloid-specific tubulin-beta isotype 5 as target antigen of antineutrophil cytoplasmic antibodies in autoimmune liver disorders [Abstract]. HEPATOLOGY 2005; 42(Suppl 1): 288A.
  • 92
    Grant AJ, Lalor PF, Hubscher SG, Briskin M, Adams DH. MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). HEPATOLOGY 2001; 33: 10651072.
  • 93
    Podolsky DK. The current future understanding of inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2002; 16: 933943.
  • 94
    Cario E, Brown D, McKee M, Lynch-Devaney K, Gerken G, Podolsky DK. Commensal-associated molecular patterns induce selective toll-like receptor-trafficking from apical membrane to cytoplasmic compartments in polarized intestinal epithelium. Am J Pathol 2002; 160: 165173.
  • 95
    Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000; 68: 70107017.
  • 96
    Inohara N, Chamaillard M, McDonald C, Nuñez G. NOD-LRR proteins: Role in host-microbial interactions and inflammatory disease. Annu Rev Biochem 2005; 74: 355383.
  • 97
    Harada K, Ohira S, Isse K, Ozaki S, Zen Y, Sato Y, et al. Lipopolysaccharide activates nuclear factor-kappa B through toll-like receptors and related molecules in cultured biliary epithelial cells. Lab Invest 2003; 83: 16571667.
  • 98
    Ge X, Uzunel M, Ericzon BG, Sumitran-Holgersson S. Biliary epithelial cell antibodies induce expression of toll-like receptors 2 and 3: A mechanism for post-liver transplantation cholangitis? Liver Transpl 2005; 11: 911921.
  • 99
    Wang AP, Migita K, Ito M, Takii Y, Daikoku M, Yokoyama T, et al. Hepatic expression of toll-like receptor 4 in primary biliary cirrhosis. J Autoimmun 2005; 25: 8591.
  • 100
    Takii Y, Nakamura M, Ito M, Yokoyama T, Komori A, Shimizu-Yoshida Y, et al. Enhanced expression of type I interferon and toll-like receptor-3 in primary biliary cirrhosis. Lab Invest 2005; 85: 908920.
  • 101
    Grant AJ, Lalor PF, Salmi M, Jalkamen S, Adams DH. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 2002; 359: 150157.
  • 102
    Adams DH, Eksteen B. Aberrant homing of mucosal T cells and extraintestinal manifestations of inflammatory bowel disease. Nat Rev Immunol: In press.
  • 103
    Salmi M, Jalkanen S. Endothelial ligands and homing of mucosal leukocytes in extraintestinal manifestations of IBD. Inflamm Bowel Dis 1998; 4: 149156.
  • 104
    Hillan KJ, Hagler KE, MacSween RN, Ryan AM, Renz Me, Chiu HH, et al. Expression of the mucosal vascular addressin, MAdCAM-1, in inflammatory liver disease. Liver 1999; 19: 509518.
  • 105
    Eksteen B, Grant AJ, Miles A, Curbishley SM, Lalor PF, Hubscher SG, et al. Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med 2004; 200: 15111517.
  • 106
    Kunkel EJ, Campbell DJ, Butcher EC. Chemokines in lymphocyte trafficking and intestinal immunity. Microcirculation 2003; 10: 313323.
  • 107
    Mora JR, Bono MR, Manjunath N, Weninger W, Cavanagh LL, Rosemblatt M, et al. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 2000; 424: 8893.
  • 108
    Heydtmann M, Lalor PF, Eksteen JA, Hubscher SG, Briskin M, Adams DH. CXC chemokine ligand 16 promotes integrin-mediated adhesion of liver-infiltrating lymphocytes to cholangiocytes and hepatocytes within the inflamed human liver. J Immunol 2005; 174: 10551062.
  • 109
    Lee YM, Kaplan MM, ACG Practice Guidelines Committee. Practice guidelines for management of primary sclerosing cholangitis. Am J Gastroenterol 2002; 97: 528534.
    Direct Link:
  • 110
    Lindor KD, the Mayo PSC/UDCA study group. Urosodiol for the treatment of primary sclerosing cholangitis. N Engl J Med 1997; 336: 691695.
  • 111
    Mitchell SA, Bansi D, Hunt N, Von Bergman K, Fleming KA, Chapman RW. A preliminary trial of high dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001; 121: 900907.
  • 112
    Harnois, DM, Angulo P, Jorgensen RA, LaRusso NF, Lindor KD. High-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001; 121: 900907.
  • 113
    Olsson R, Boberg KM, Schaffalitsky de Muckadell O, Lindgren S, Hultcrantz R, Folvik G, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: A 5-year multicenter, randomized, controlled study. Gastroenterology 2005; 129: 14641472.
  • 114
    Hoofnagle JH. This month from the NIH: Primary sclerosing cholangitis. HEPATOLOGY 2005; 41: 955.
  • 115
    Sekhon JS, Chung RT, Epstein M, Kaplan MM. Steroid-responsive (autoimmune) sclerosing cholangitis. Dig Dis Sci 2005; 50: 18391843.
  • 116
    Kaplan MT. Toward better treatment for primary sclerosing cholangitis. N Engl J Med 1997; 336: 719721.
  • 117
    Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized controlled trial. Gastroenterology 1988; 94: 488493.
  • 118
    Marschall HU, Wagner M, Zollner G, Fickert P, Dicafalusy U, Gumhold J, et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 2005; 129: 476485.
  • 119
    Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001; 134: 8995.
  • 120
    Pardi DS, Loftus EV, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemoprotective agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003; 124: 889893.
  • 121
    Olsson R, Bjornsson E, Backman L, Friman S, Hockerstedt K, Kaijser B, et al. Bile duct bacterial isolates in primary sclerosing cholangitis: a study of explanted liver. J Hepatol 1988; 28: 426432.
  • 122
    Serfaty L, De Leusse A, Rosmorduc O, Desaint B, Flejou JF, Chazouilleres O, et al. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in primary biliary cirrhosis: An observational study. HEPATOLOGY 2003; 38: 203209.
  • 123
    Battezzati PM, Zuin M, Crosignani A, Allocca M, Invernizzi P, Selmi C, et al. Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients. Aliment Pharmacol Ther 2001; 15: 14271434.
  • 124
    Ahrendt SA, Pitt HA, Kalloo AN, Venbrux AC, Klein AS, Herlong HF, et al. Primary sclerosing cholangitis: Resect, dilate or transplant? Ann Surg 1998; 227: 412423.
  • 125
    May GR, Bender CE, LaRusso NF, Wiesner RH. Nonoperatative dilation of dominant strictures in primary sclerosing cholangitis. Am J Roentgenol 1985; 145: 10611064.
  • 126
    Johnson GK, Greenen JE, Venu RP, Schmalz MJ, Hogan WJ. Endoscopic treatment of biliary tract strictures in sclerosing cholangitis: A larger series and recommendation for treatment. Gastrointest Endosc 1991; 37: 3843.
  • 127
    Gaing AA, Geders JM, Cohen SA, Siege JH. Endoscopic management of primary sclerosing cholangitis: review and report of an open series. Gastroenterology 1993; 88: 20002008.
  • 128
    Grijm R, Huibregtse K, Bartelsman J, Mathus-Vliegen EM, Dekker W, Tytgat GN. Therapeutic investigations in primary sclerosing cholangitis. Dig Dis Sci 1986; 31: 792798.
  • 129
    Lee JG, Schutz SM, England RE, Leung JW, Cotton PB. Endoscopic therapy of sclerosing cholangitis. HEPATOLOGY 1995; 21: 661667.
  • 130
    Baluyut AR, Sherman S, Lehman GA, Hoen H, Chalasani N. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc 2001; 53: 308312.
  • 131
    Huibregtse K, Tytgat GNJ. Palliative treatment of obstructive jaundice by transpapillary introduction of large bore bile duct endoprosthesis. Gut 1982; 23: 371375.
  • 132
    van Milligen de Wit AW, van Bracht J, Rauws AEJ, Jones EA, Tytgat GN, Huibregtse K. Endocopic stent therapy for dominant extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest Endosc 1996; 44: 293299.
  • 133
    van Milligen de Wit AW, Rauws EA, van Bracht J, Mulder CJ, Jones EA, Tytgat GN, et al. Lack of complications following short term stent therapy for extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest Endosc 1997; 46: 344347.
  • 134
    Wagner S, Gebel M, Meier P, Trautwein C, Bleck J, Nashan B, Manns MP. Endoscopic management of biliary tract strictures in primary sclerosing cholangitis. Endoscopy 1996; 7: 546551.
  • 135
    Ponsioen CY, Lam K, van Milligen de Wit AW, Huibregtse K, Tytgat GN. Four years experience with short term stenting in primary sclerosing cholangitis. Am J Gastroenterol 1999; 94: 24032407.
    Direct Link:
  • 136
    Linder S, Soderlund C. Endoscopic therapy in primary sclerosing cholangitis: outcome of treatment and risk of cancer. Hepato-Gastroenterol 2001; 48: 387392.
  • 137
    Lee JG, Schutz SM, England RE, Leung JW, Cotton PB. Endoscopic therapy of sclerosing cholangitis. HEPATOLOGY 1995; 21: 661667.
  • 138
    van den Hazel SJ, Wolfhagen EH, van Buuren HR, van de Meeberg PC, Van Leeuwen DJ. Prospective risk assessment of endoscopic retrograde cholangiography in patients with primary sclerosing cholangitis. Dutch PSC Study Group. Endoscopy 2000; 32: 779782.
  • 139
    Boyer JL. Nuclear receptor ligands: Rational and effective therapy for chronic cholestatic liver disease? Gastroenterology 2005; 129: 735740.
  • 140
    Angulo P, Batts KP, Jorgensen RA, LaRusso NA, Lindor KD. Oral budesonide in the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000; 95: 23332337.
    Direct Link:
  • 141
    Van Thiel DH, Carroll P, Abu-Elmagd K, Rodriguez-Rilo H, Irish W, McMichael J, et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol 1995; 90: 455459.
  • 142
    Knox TA, Kaplan MM. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology 1994; 106: 494499.
  • 143
    Lindor KD, Jorgensen RA, Anderson ML, Gores GL, Hofmann AF, LaRusso NF. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: A pilot study. Am J Gastroenterol 1996; 91: 511515.
  • 144
    Talwalkar JA, Angulo P, Keach JC, Petz JL, Jorgensen RA, Lindor, KD. Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2005; 100: 308312.
    Direct Link:
  • 145
    Bharucha AE, Jorgensen R, Lichtman SN, LaRusso NF, Lindor KD. A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000; 95: 23382342.
    Direct Link:
  • 146
    Ball KR, Kowdley KV. A review of silybum marianum (milk thistle) as a treatment of alcoholic liver disease. J Clin Gastroenterol 2005; 39: 520528.
  • 147
    Epstein MP, Kaplan MM. A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Dig Dis Sci 2004; 49: 14.
  • 148
    Farkkila M, Karvonen AL, Nurmi J, Nuutinen H, Taavitsainen M, Pikkarainen P, et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: A randomized placebo-controlled trial. HEPATOLOGY 2004; 40: 13791386.
  • 149
    Angulo P, MacCarty RL, Sylvestre PB, Jorgensen RA, Wiesner RH, LaRusso NA, et al. Pirfenidone in the treatment of primary sclerosing cholangitis. Dig Dis Sci 2002; 47: 157161.
  • 150
    Brandsaeter B, Isoniemi H, Broome U, Olausson M, Backman L, Hansen B, et al. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol 2004; 40: 815822.
  • 151
    Wiesner RH. Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: predicting outcomes with natural history models. Mayo Clin Proc 1978; 73: 575588.
  • 152
    Ricci P, Therneau TM, Malinchoc M, Benson JT, Petz JL, Klintmalm GB, et al. A prognostic model for the outcome of liver transplantation in patients with cholestatic liver disease. HEPATOLOGY 1997; 25: 672677.
  • 153
    Freeman RB, Wiesner RH, Edwards E, Harper A, Merion RM, Wolfe RA. Results of the first year of the new liver allocation plan. Liver Transpl 2004; 10: 715.
  • 154
    Merion RM, Schaubel DE, Dystra DM, Freeman RB, Port FK, Wolfe RA. The survival benefit of liver transplantation. Am J Transplant 2005; 5: 307313.
  • 155
    Roberts MS, Angus DC, Bryce CL, Valenta Z, Weissfeld L. Survival after liver transplantation in the United States: A disease-specific analysis of the UNOS database. Liver Transpl 2004; 10: 886897.
  • 156
    U.S. Organ Procurement and Transplantation Network and the Scientific Registry for Transplant Recipients. Annual Report: Transplant Data 1994-2003. Department of Health and Human Services, Health Resources and Services Administration, Office of Special Programs, Division of Transplantation, Rockville, MD. United Network for Organ Sharing, Richmond, VA; University Renal Research and Education Association, Ann Arbor, MI, 2004.
  • 157
    McDiarmid SV, Anand R, SPLIT Research Group. Studies of pediatric liver transplantation (SPLIT): A summary of the 2003 annual report. Clin Transpl 2003; 119130.
  • 158
    Harrison RF, Davies MH, Neuberger JM, Hubscher SG. Fibrous and obliterative cholangitis in liver allografts: Evidence of recurrent primary sclerosing cholangitis? HEPATOLOGY 1994; 20: 356361.
  • 159
    Lerut J, Demetris AJ, Stieber AC, Marsh JW, Gordon RD, Esquivel CO, et al. Intrahepatic bile duct strictures after human orthotopic liver transplantation. Recurrence of primary sclerosing cholangitis or unusual presentation of allograft rejection? Transpl Int 1988; 1: 127130.
  • 160
    Feller RB, Waugh RC, Selby WS, Dolan PM, Sheil AG, McCaughan GW. Biliary strictures after liver transplantation: Clinical picture, correlates and outcomes. J Gastroenterol Hepatol 1996; 11: 2125.
  • 161
    Jeyarajah DR, Netto GJ, Lee SP, Testa G, Abbasoglu O, Husberg BS, et al. Recurrent primary sclerosing cholangitis after orthotopic liver transplantation: Is chronic rejection part of the disease process? Transplantation 1998; 66: 13001306.
  • 162
    Goss JA, Shackleton CR, Farmer DG, Arnaout WS, Seu P, Markowitz JS, et al. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. Ann Surg 1997; 225: 472481.
  • 163
    Grzaiadei IW. Recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2002; 8: 575581.
  • 164
    Gopal DV, Corless CL, Rabkin JM, Olyaei AJ, Rosen HR. Graft failure from severe recurrent primary sclerosing cholangitis following orthotopic liver transplantation. J Clin Gastroenterol 2003; 37: 344347.
  • 165
    Khettry U, Keaveny A, Goldar-Najafi A, Lewis WD, Pomfret EA, Pomposelli JJ, et al. Liver transplantation for primary sclerosing cholangitis: A long-term clinicopathologic study. Hum Pathol 2003; 34: 11271136.
  • 166
    Kugelmas M, Spiegelman P, Osgood MJ, Young DA, Trotter JF, Steinberg T, et al. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2003; 9: 727732.
  • 167
    Vera A, Gunson BK, Ussatoff V, Nightingale P, Candinas D, Radley S, et al. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation 2003; 75: 19831988.
  • 168
    Haagsma EM, Van Den Berg AP, Kleibeuker JH, Slooff MJ, Dijkstra G. Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens. Aliment Pharmacol Ther 2003; 18: 3344.
  • 169
    Heneghan MA, Tuttle-Newhall JE, Suhocki PV, Muir AJ, Morse M, Bornstein JD, et al. De-novo cholangiocarcinoma in the setting of recurrent primary sclerosing cholangitis following liver transplant. Am J Transplant 2003; 3: 634638.
  • 170
    Fabia R, Levy MF, Testa G, Obiekwe S, Goldstein RM, Husberg BS, et al. Colon carcinoma in patients undergoing liver transplantation. Am J Surg 1998; 176: 265269.
  • 171
    Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. HEPATOLOGY 2001; 33: 13531357.
  • 172
    Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarinoma in the United States: A true increase? J Hepatol 2004; 40: 472477.
  • 173
    Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002; 2: 10.
  • 174
    Donato F, Gelatti U, Tagger A, Favret M, Ribero ML, Callea F, et al. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: A case-control study in Italy. Cancer Causes Control 2001; 12: 959964.
  • 175
    Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: A case-control study. Gastroenterology 2005; 128: 620626.
  • 176
    Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Loof L, Danielsson A, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002; 36: 321327.
  • 177
    Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004; 99: 523526.
    Direct Link:
  • 178
    Stiehl A, Rudolph G, Kloters-Plachky P, Sauer P, Walker S. Development of bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid. outcome after endoscopic treatment. J Hepatol 2002; 36: 151156.
  • 179
    Gores GJ. Early detection and treatment of cholangiocarinoma. Liver Transpl 2000; 6: S30S34.
  • 180
    Kaya M, de Groen PC, Angulo P, Nagorney DM, Gunderson LL, Gores GJ, et al. Treatment of cholangiocarcinoma complicating primary sclerosing cholangitis: The Mayo Clinic experience. Am J Gastroenterol 2001; 96: 11641169.
    Direct Link:
  • 181
    Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R. Serum tumor markers of the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1995; 108: 856869.
  • 182
    Fleming KA, Boberg KM, Glaumann H, Bergquist A, Smith D, Clausen OP. Biliary dysplasia as a marker of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2001; 34: 360365.
  • 183
    Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by an NO-dependent mechanism. Cancer Res 2000; 60: 184190.
  • 184
    Jaiswal M, LaRusso NF, Shapiro RA, Billiar TR, Gores GJ. Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes. Gastroenterology 2001; 120: 190199.
  • 185
    Jaiswal M, LaRusso NF, Nishioka K, Nakabeppu Y, Gores GJ. Human Ogg1, a protein involved in the repair of 8-oxoguanine, is inhibited by nitric oxide. Cancer Res 2001; 61: 63886493.
  • 186
    Jaiswal M, LaRusso NF, Gores GJ. Cholangiocarcinoma and pro-inflammatory cytokines. Cancer Res Alert 2000; 1: 141143.
  • 187
    Jaiswal M, LaRusso NF, Gores GJ. Nitric oxide in gastrointestinal epithelial cell carcinogenesis: Linking inflammation to oncogenesis. Am J Physiol 2001; 281: G626G634.
  • 188
    Ishimura N, Bronk SF, Gores GF. Inducible nitric oxide synthase upregulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis. Gastroenterology 2005; 128: 13541368.
  • 189
    Alessiani M, Tzakis A, Todo S, Demetris AJ, Fung JJ, Starzl TE. Assessment of five year experience with abdominal organ cluster transplantation. J Am Coll Surg 1995; 180: 19.
  • 190
    Goldstein RM, Stone M, Tillery GW, Senzer N, Levy M, Husberg BS, et al. Is liver transplantation indicated for cholangiocarcinoma? Am J Surg 1993; 166: 768771.
  • 191
    Iwatsuki S, Todo S, Marsh JW, Madariaga JR, Lee RG, Dvorchik I, et al. Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg 1998; 187: 358364.
  • 192
    Jonas S, Mittler J, Pascher A, Theruvath T, Thelen A, Klupp J, et al. Extended indications in living-donor liver transplantation: bile duct cancer. Transplantation 2005; 80(1 Suppl ): S101S104.
  • 193
    Lang H, Kaiser G, Zopf T, Sotiropoulos GC, Frilling A, Malago M, Broelsch CE. [ Surgical therapy of hilar cholangiocarcinoma.] Chirurg 2006; 77: 325334.
  • 194
    Lang H, Sotiropoulos GC, Dömland M, Frühauf NR, Paul A, Kind EM, et al. Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC) — when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period. Ann Surg 2005; 241: 134143.
  • 195
    Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 2000; 69: 16331637.
  • 196
    Pichlmayr R, Weimann A, Klempnauer J, Oldhafer KJ, Maschek H, Tusch G, et al. Surgical treatment in proximal bile duct cancer: A single-center experience. Ann Surg 1996; 224: 628638.
  • 197
    Rea JG, Heimback JK, Rosen CB, Gores GJ, Haddock MG, Alberts SR, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005; 242: 451458.
  • 198
    Shimoda M, Farmer DG, Colquhoun SD, Rosove M, Ghobrial RM, Yersiz H, et al. Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature. Liver Transpl 2001; 7: 10231033.
  • 199
    Sudan D, DeRoover A, Chinnakotla S, Fox I, Shaw B, McCashland T, et al. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant 2002; 2: 774779.
  • 200
    De Vreede I, Steers JL, Burch PA, Rosen CB, Gunderson LL, Haddock MG, et al. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transplant 2000; 6: 317319.